Current and historical daily PE Ratio for MorphoSys AG (
XSWX:MOR
) from 1999 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. MorphoSys AG stock (XSWX:MOR) PE ratio as of May 24 2024 is 0.
More Details
MorphoSys AG (XSWX:MOR) PE Ratio (TTM) Chart
MorphoSys AG (XSWX:MOR) PE Ratio (TTM) Historical Data
View and export this data going back to 1999. Start your Free Trial
Total 959
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| MorphoSys AG PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-24 | At Loss | 2022-12-30 | At Loss |
| 2023-03-03 | At Loss | 2022-12-29 | At Loss |
| 2023-03-02 | At Loss | 2022-12-28 | At Loss |
| 2023-03-01 | At Loss | 2022-12-27 | At Loss |
| 2023-02-28 | At Loss | 2022-12-23 | At Loss |
| 2023-02-27 | At Loss | 2022-12-22 | At Loss |
| 2023-02-24 | At Loss | 2022-12-21 | At Loss |
| 2023-02-23 | At Loss | 2022-12-20 | At Loss |
| 2023-02-22 | At Loss | 2022-12-19 | At Loss |
| 2023-02-21 | At Loss | 2022-12-16 | At Loss |
| 2023-02-20 | At Loss | 2022-12-15 | At Loss |
| 2023-02-17 | At Loss | 2022-12-14 | At Loss |
| 2023-02-16 | At Loss | 2022-12-13 | At Loss |
| 2023-02-15 | At Loss | 2022-12-12 | At Loss |
| 2023-02-14 | At Loss | 2022-12-09 | At Loss |
| 2023-02-13 | At Loss | 2022-12-08 | At Loss |
| 2023-02-10 | At Loss | 2022-12-07 | At Loss |
| 2023-02-09 | At Loss | 2022-12-06 | At Loss |
| 2023-02-08 | At Loss | 2022-12-05 | At Loss |
| 2023-02-07 | At Loss | 2022-12-02 | At Loss |
| 2023-02-06 | At Loss | 2022-12-01 | At Loss |
| 2023-02-03 | At Loss | 2022-11-30 | At Loss |
| 2023-02-02 | At Loss | 2022-11-29 | At Loss |
| 2023-02-01 | At Loss | 2022-11-28 | At Loss |
| 2023-01-31 | At Loss | 2022-11-25 | At Loss |
| 2023-01-30 | At Loss | 2022-11-24 | At Loss |
| 2023-01-27 | At Loss | 2022-11-23 | At Loss |
| 2023-01-26 | At Loss | 2022-11-22 | At Loss |
| 2023-01-25 | At Loss | 2022-11-21 | At Loss |
| 2023-01-24 | At Loss | 2022-11-18 | At Loss |
| 2023-01-23 | At Loss | 2022-11-17 | At Loss |
| 2023-01-20 | At Loss | 2022-11-16 | At Loss |
| 2023-01-19 | At Loss | 2022-11-15 | At Loss |
| 2023-01-18 | At Loss | 2022-11-14 | At Loss |
| 2023-01-17 | At Loss | 2022-11-11 | At Loss |
| 2023-01-16 | At Loss | 2022-11-10 | At Loss |
| 2023-01-13 | At Loss | 2022-11-09 | At Loss |
| 2023-01-12 | At Loss | 2022-11-08 | At Loss |
| 2023-01-11 | At Loss | 2022-11-07 | At Loss |
| 2023-01-10 | At Loss | 2022-11-04 | At Loss |
| 2023-01-09 | At Loss | 2022-11-03 | At Loss |
| 2023-01-06 | At Loss | 2022-11-02 | At Loss |
| 2023-01-05 | At Loss | 2022-11-01 | At Loss |
| 2023-01-04 | At Loss | 2022-10-31 | At Loss |
| 2023-01-03 | At Loss | 2022-10-28 | At Loss |
MorphoSys AG (XSWX:MOR) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
MorphoSys AG
ISIN : DE0006632003
Share Class Description:
XSWX:MOR: Ordinary SharesCompare
Compare
Traded in other countries / regions
MOR.USAMOR.Germany0NDV.UK1MOR.ItalyMOR.AustriaMOR.Switzerland IPO Date
1999-03-09Description
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers